Cryosurgical ablation of the prostate: Two-year prostate-specific antigen and biopsy results

Urology

Volumn 47, Issue 3, 1996, Pages 395-401

  Cohen, Jeffrey K ^a   Miller Jr , Ralph J ^a   Rooker, Gina M ^a   Shuman, Barry A ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CRYOSURGERY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; TREATMENT OUTCOME;

EID: 0029877547     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80459-2     Document Type: Article

References (11)

1. Kavadi VS, Zagers GK, and Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Biol Phys 30: 279-287, 1994.
2. Crook JM, Perry GA, Robertson S, and Esche BA: Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45: 624-632, 1995.
3. Stamey TA, Ferrari MK, and Schmid HP: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 150: 1856-1859, 1993.
4. Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, and Baust J: Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 72: 1291-1299, 1993.
5. Cohen JK, Miller RJ, and Shuman BA: Urethral warming catheter for use during cryoablation of the prostate. Urology 45: 861-864, 1995.
6. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993.
7. Egawa S, Wheeler TM, Greene DR, and Scardino DT: Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology 39: 358-363, 1992.
8. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, and Stamey TA: Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142: 326-331, 1989.
9. Lee WR, Hanks GE, Schultheiss TE, Corn BW, and Hunt MA: Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 13: 464-469, 1995.
10. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154 (part 1): 424-428, 1995.
11. Van Poppel JV, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, and Baert L: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 154: (part 1): 429-434, 1995.